https://mindmedicinelaw.com/briefing/fda-s-proposed-changes-to-drug-registration-impact-on-psychedelics-20260713-21561The Psychedelic Journalen2026-07-13T15:04:20.822358+00:00FDA's Proposed Changes to Drug Registration: Impact on PsychedelicsFDA, drug registration, psychedelic manufacturing, distributed manufacturing, foreign establishments, regulatory compliance, PREVENT Pandemics Act, market entry, psychedelic industry, drug listing requirementshttps://mindmedicinelaw.com/briefing/ect-study-glutathione-homocysteine-not-linked-to-depression-outcome-20260711-21642The Psychedelic Journalen2026-07-13T15:04:59.440795+00:00ECT Study: Glutathione, Homocysteine Not Linked to Depression Outcomeelectroconvulsive therapy, glutathione, homocysteine, treatment-resistant depression, biomarkers, oxidative stress, bipolar disorder, unipolar disorderhttps://mindmedicinelaw.com/briefing/epigenetic-impact-of-ketamine-mdma-on-brain-health-20260711-21597The Psychedelic Journalen2026-07-13T15:04:09.880966+00:00Epigenetic Impact of Ketamine & MDMA on Brain Healthketamine, MDMA, epigenetic changes, neuroplasticity, neuroimmune regulation, psychiatric health, clinical trials, psychoplastogens, DNA methylation, therapeutic strategieshttps://mindmedicinelaw.com/briefing/u-s-bill-aims-to-enhance-psychedelic-treatment-for-veterans-20260711-21634The Psychedelic Journalen2026-07-13T15:03:58.651623+00:00U.S. Bill Aims to Enhance Psychedelic Treatment for Veteranspsychedelic treatment, veterans, PTSD, psilocybin, legislation, clinical trials, mental health, policy, research, Department of Defensehttps://mindmedicinelaw.com/briefing/mdma-therapy-s-impact-on-discrimination-trauma-symptoms-20260711-21275The Psychedelic Journalen2026-07-12T15:05:02.603472+00:00MDMA Therapy's Impact on Discrimination Trauma SymptomsMDMA-assisted therapy, discrimination trauma, psychedelic research, culturally-informed treatment, clinical trials, mental health policy, marginalized populations, posttraumatic stress disorder, psychotherapy, public healthhttps://mindmedicinelaw.com/briefing/propofol-ketamine-vs-propofol-fentanyl-in-d-c-anesthesia-20260711-21291The Psychedelic Journalen2026-07-12T15:04:53.291751+00:00Propofol-Ketamine vs. Propofol-Fentanyl in D&C Anesthesiapropofol-ketamine, propofol-fentanyl, hemodynamic stability, Dilatation and Curettage, anesthesia, peri-operative complications, analgesia, clinical trials, anesthetic practices, ketaminehttps://mindmedicinelaw.com/briefing/doj-faces-scrutiny-over-halt-fentanyl-act-deadline-20260711-21211The Psychedelic Journalen2026-07-11T22:04:44.510510+00:00DOJ Faces Scrutiny Over HALT Fentanyl Act DeadlineHALT Fentanyl Act, DOJ delay, drug scheduling, fentanyl analogues, regulatory clarity, drug policy, research implications, enforcement priorities, controlled substances, policy impacthttps://mindmedicinelaw.com/briefing/comp360-psilocybin-in-depression-clinical-insights-and-implications-20260711-21209The Psychedelic Journalen2026-07-11T22:04:36.506850+00:00COMP360 Psilocybin in Depression: Clinical Insights and ImplicationsCOMP360 psilocybin, treatment-resistant depression, psychedelic therapy, clinical trials, mental health treatment, neuroplasticity, FDA approval, psychiatric research, regulatory implications, ethical considerationshttps://mindmedicinelaw.com/briefing/personality-shifts-in-german-students-post-psychedelic-use-20260710-21098The Psychedelic Journalen2026-07-12T22:04:04.010317+00:00Personality Shifts in German Students Post-Psychedelic Usepsychedelic research, personality changes, German students, Openness, Conscientiousness, non-clinical settings, Big Five Inventory, Berlin college students, psychedelic use, neurosciencehttps://mindmedicinelaw.com/briefing/anesthetic-agents-influence-ect-seizure-duration-and-cognition-20260710-21145The Psychedelic Journalen2026-07-12T22:03:56.264639+00:00Anesthetic Agents Influence ECT Seizure Duration and Cognitionelectroconvulsive therapy, anesthetic agents, seizure duration, cognitive recovery, etomidate, ketamine, propofol, randomized controlled trials, mental health treatment, evidence-based guidelineshttps://mindmedicinelaw.com/briefing/future-drug-targets-in-depression-treatment-emerging-therapies-20260710-21146The Psychedelic Journalen2026-07-12T22:03:48.366919+00:00Future Drug Targets in Depression Treatment: Emerging Therapiesdepression treatment, NMDA receptor modulators, pharmacogenomics, personalized medicine, rapid-acting antidepressants, glutamatergic dysfunction, neuroinflammation, brain-derived neurotrophic factor, artificial intelligence in drug discovery, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/digital-technologies-and-altered-states-a-new-frontier-20260710-21097The Psychedelic Journalen2026-07-12T22:03:41.771199+00:00Digital Technologies and Altered States: A New Frontierdigital technologies, altered states of consciousness, virtual reality, biofeedback, artificial intelligence, digital therapeutics, psychophysiological effects, clinical applications, market opportunities, mental healthhttps://mindmedicinelaw.com/briefing/spontaneous-recovery-in-fear-conditioning-implications-for-ptsd-20260710-21276The Psychedelic Journalen2026-07-12T22:03:32.055514+00:00Spontaneous Recovery in Fear Conditioning: Implications for PTSDspontaneous recovery, fear conditioning, PTSD treatment, anxiety relapse, pharmacological interventions, non-pharmacological methods, exposure therapy, clinical trials, neuroscience research, mental health policyhttps://mindmedicinelaw.com/briefing/new-voluntary-fentanyl-intake-model-in-mice-shows-dependence-20260710-21302The Psychedelic Journalen2026-07-12T15:05:33.495319+00:00New Voluntary Fentanyl Intake Model in Mice Shows Dependencevoluntary fentanyl intake, opioid dependence model, dose-dependent withdrawal, sex differences in addiction, opioid crisis research, preclinical opioid model, naloxone-precipitated withdrawal, mice opioid studies, opioid addiction mechanisms, public health strategieshttps://mindmedicinelaw.com/briefing/epigenetic-impacts-of-psychedelics-and-ketamine-in-neuromodulation-20260710-21314The Psychedelic Journalen2026-07-12T15:05:24.971621+00:00Epigenetic Impacts of Psychedelics and Ketamine in Neuromodulationepigenetic changes, psychedelics, ketamine, neuromodulation, clinical trials, mental healthhttps://mindmedicinelaw.com/briefing/gdnf-overexpression-alters-temperament-in-rats-implications-for-psychiatric-trea-20260710-21259The Psychedelic Journalen2026-07-12T15:05:11.296524+00:00GDNF Overexpression Alters Temperament in Rats: Implications for Psychiatric TreatmentGDNF, temperament, psychiatric disorders, neurotrophic factors, dopamine transporter, serotonin neurotransmission, animal models, neuroscience, treatment development, clinical trialshttps://mindmedicinelaw.com/briefing/innovations-in-psychedelic-therapeutics-5-ht2a-and-aerosol-delivery-20260710-21315The Psychedelic Journalen2026-07-12T15:04:44.080141+00:00Innovations in Psychedelic Therapeutics: 5-HT2A and Aerosol Deliverypsychedelic therapeutics, 5-HT2A receptor, aerosol delivery, 5-MeO-DMT, neuropsychiatric treatment, serotonergic medicine, clinical trials, drug delivery systems, psychedelic research, mental healthhttps://mindmedicinelaw.com/briefing/psychedelics-enhance-reward-responsiveness-in-rats-20260710-21133The Psychedelic Journalen2026-07-11T22:05:01.782478+00:00Psychedelics Enhance Reward Responsiveness in Ratspsychedelics, reward responsiveness, anhedonia, psilocybin, ketamine, 5-HT 2A receptor, preclinical study, psychiatric disorders, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/future-drug-targets-for-depression-emerging-therapies-20260710-21144The Psychedelic Journalen2026-07-11T22:04:53.356392+00:00Future Drug Targets for Depression: Emerging Therapiesdepression treatment, precision medicine, rapid-acting therapies, ketamine, clinical trials, pharmacogenomics, personalized medicine, novel antidepressants, NMDA receptor modulators, psychiatric disordershttps://mindmedicinelaw.com/briefing/psychedelic-assisted-psychosexual-therapy-emerging-frontiers-20260710-21118The Psychedelic Journalen2026-07-11T22:04:17.373497+00:00Psychedelic-Assisted Psychosexual Therapy: Emerging Frontierspsychedelic-assisted therapy, psychosexual dysfunction, psilocybin, MDMA, clinical trials, mental health, altered states of consciousness, therapeutic landscapes, policy implications, empathogenic agentshttps://mindmedicinelaw.com/briefing/sex-specific-psilocybin-effects-in-stress-research-new-insights-20260709-21605The Psychedelic Journalen2026-07-13T15:04:45.177589+00:00Sex-Specific Psilocybin Effects in Stress Research: New Insightspsilocybin research, sex-specific effects, developmental stress, mental health disorders, psychedelic treatments, neuroscience, clinical trials, translational validity, behavioral phenotyping, personalized medicinehttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treating-addiction-and-depression-potential-and-risks-20260709-21651The Psychedelic Journalen2026-07-13T15:04:32.798994+00:00Ketamine's Role in Treating Addiction and Depression: Potential and Risksketamine, addiction treatment, treatment-resistant depression, neuroplastic effects, substance use disorders, clinical trials, psychotherapy integration, NMDA receptor antagonism, drug misuse risk, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/digital-tool-enhances-alzheimer-s-therapy-eligibility-assessment-20260709-21317The Psychedelic Journalen2026-07-12T22:04:12.770878+00:00Digital Tool Enhances Alzheimer's Therapy Eligibility Assessmentdigital cognitive assessment, MMSE scores, Alzheimer's therapy, health disparities, machine learning, Bio-Hermes-001 study, DCR tool, healthcare policy, digital triage, data privacyhttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-human-neural-stem-cells-mechanisms-and-implications-20260709-21099The Psychedelic Journalen2026-07-11T22:04:26.831957+00:00DMT's Impact on Human Neural Stem Cells: Mechanisms and ImplicationsDMT, neural stem cells, neurogenesis, psychedelic research, antidepressant effects, neurotrophins, clinical applications, neural plasticity, mental health treatment, psychedelic therapy